×
About 11,535 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  3,057 results

Lights and shadows on JAK inhibitors for Ankylosing Spondylitis.
https://doi.org/10.1016/j.ejim.2022.05.018
European Journal of Internal Medicine; Benanti G, Dagna L et. al.

May 24th, 2022 - Lights and shadows on JAK inhibitors for Ankylosing Spondylitis.|2022|Benanti G,Dagna L,Campochiaro C,|

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyl...
https://clinicaltrials.gov/ct2/show/NCT04436640

May 20th, 2022 - The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and...

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
https://clinicaltrials.gov/ct2/show/NCT04929210

May 20th, 2022 - PsA is a chronic inflammatory musculoskeletal disease that has 6 disease domains, and axial disease represents one of the domains. Guselkumab is a fully human immunoglobulin (Ig) G1 lambda monoclonal antibody (mAb) that by binding to the p19 prote...

Associations between IL-23R gene polymorphism (rs10889677 A/C) and ankylosing spondylit...
https://doi.org/10.1080/08916934.2022.2076837
Autoimmunity Zhang T, Yu L et. al.

May 19th, 2022 - Autoimmune diseases are a kind of chronic diseases for which the immune system loses tolerance to autoantigens. This meta-analysis' purpose is to determine whether there exists a correlation between IL-23R polymorphism and common autoimmune diseas...

Serum leptin concentration is associated with the attainment of clinical outcomes in pa...
https://doi.org/10.55563/clinexprheumatol/ou570o
Clinical and Experimental Rheumatology; Hernández-Breijo B, Novella-Navarro M et. al.

May 18th, 2022 - To analyse the influence of adipokines on attaining the clinical outcomes in patients with axial spondyloarthritis (axSpA) treated with TNF inhibitors (TNFi), and then, to investigate the association of patients' characteristics and adipokine conc...

see more →

Guidelines  11 results

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients ...
https://www.ncbi.nlm.nih.gov/pubmed/30717501
Pain Physician; Kaye AD, Manchikanti L et. al.

Feb 6th, 2019 - Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in ...

The effectiveness, safety, and economic evaluation of Korean medicine for unexplained i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779787
Medicine

Mar 6th, 2018 - Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the ...

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
https://doi.org/10.1136/annrheumdis-2016-210770
Annals of the Rheumatic Diseases; van der Heijde D, Ramiro S et. al.

Jan 15th, 2017 - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with...

EULAR recommendations for cardiovascular disease risk management in patients with rheum...
https://doi.org/10.1136/annrheumdis-2016-209775
Annals of the Rheumatic Diseases; Agca R, Heslinga SC et. al.

Oct 5th, 2016 - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommend...

see more →

Drugs  816 results see all →

Clinicaltrials.gov  140 results

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
https://clinicaltrials.gov/ct2/show/NCT04929210

May 20th, 2022 - PsA is a chronic inflammatory musculoskeletal disease that has 6 disease domains, and axial disease represents one of the domains. Guselkumab is a fully human immunoglobulin (Ig) G1 lambda monoclonal antibody (mAb) that by binding to the p19 prote...

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyl...
https://clinicaltrials.gov/ct2/show/NCT04436640

May 20th, 2022 - The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and...

Physiotherapy Protocols in Treating Plantar Fasciitis
https://clinicaltrials.gov/ct2/show/NCT04967703

May 11th, 2022 - Sixty nine patients having unilateral chronic plantar fasciitis will be recruited for the study from Al-Qurayyat General Hospital, in Al-Jouf Region, Saudi Arabia. The inclusion criteria were as follows: patients suffered planter fasciitis of more...

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
https://clinicaltrials.gov/ct2/show/NCT02552212

May 11th, 2022 - Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo. The primary objective is ...

TNFα Monoclonal Antibody for Acute Spinal Cord Injury
https://clinicaltrials.gov/ct2/show/NCT04988425

May 9th, 2022 - The purpose of this study is to evaluate the safety and effectiveness of subcutaneous injection of TNFα monoclonal antibody cells for the treatment of traumatic acute spinal cord injury. Spinal cord injury can be divided into three phases, which a...

see more →

News  581 results

Upadacitinib Earns FDA Approval for Ankylosing Spondylitis 
https://www.medscape.com/viewarticle/973230

May 2nd, 2022 - The US Food and Drug Administration has approved upadacitinib (Rinvoq) as an oral treatment for active ankylosing spondylitis in adults, its manufacturer AbbVie announced April 29. Upadacitinib, a selective and reversible Janus kinase inhibitor, i...

IBD Risk 'Uncertain' in Biologic-Treated Patients With AxSpA
https://www.medscape.com/viewarticle/972907

Apr 28th, 2022 - Considerable uncertainty surrounds whether people with axial spondyloarthritis (axSpA) who are treated with biologic drugs have an increased risk for developing inflammatory bowel disease (IBD) that is higher than if they receive other treatments,...

Hypocaloric Diet Controls Joint Activity in Psoriatic Arthritis, Regardless of Weight Loss
https://www.medscape.com/viewarticle/972197

Apr 14th, 2022 - A 12-week hypocaloric diet provided suitable control of joint disease activity in patients with psoriatic arthritis (PsA), regardless of weight loss, Brazilian researchers found. Earlier research has reported that weight loss improves the symptoms...

EULAR CVD Management Guidance Focuses on Gout, Lupus, Vasculitis
https://www.medscape.com/viewarticle/969087

Feb 24th, 2022 - New recommendations from the European Alliance of Associations for Rheumatology (EULAR) provide both broad and detailed advice for cardiovascular risk management in various rheumatic and musculoskeletal diseases (RMDs), many of which can lead to a...

Guselkumab Controls Axial Involvement in PsA Through 2 Years
https://www.medscape.com/viewarticle/968302

Feb 10th, 2022 - Guselkumab (Tremfya) received Food and Drug Administration approval for the treatment of psoriatic arthritis (PsA) almost 2 years ago on the basis of a phase 3 trial, but a new substudy from that trial has now demonstrated long-term benefit in the...

see more →

Patient Education  9 results see all →